The PIVOT-02 study analyzed the use of bempegaldesleukin (BEMPEG), a pegylated interleukin-2 cytokine prodrug, in combination with nivolumab for the treatment of advanced/metastatic urothelial carcinoma (aUC). The combination provided beneficial antitumor activity in patients as a first-line treatment, and displayed benefits over immune checkpoint inhibitor monotherapy. The PIVOT-10 trial has expanded on this research by further investigating this treatment combination in cisplatin-ineligible patients with previously untreated mUC. ...
Advanced Urothelial Carcinoma
Advertisement
Latest News
At ESMO Congress 2024, Drs. Petros Grivas, Bernadett Szabados, and Karine Tawagi discuss ctDNA biomarkers.
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
Drs. Tawagi, Nizam encourage earlier monitoring and intervention to mitigate EV-induced neuropathy in certain patients.
Better quality of life and higher optimism showed to alter the perception people with metastatic disease have about cure.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
EV/pembro may offer first-line PFS and OS benefit in patients with la/mUC, regardless of Nectin-4 expression.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Advertisement
Section Editor
Amanda Nizam, MDGenitourinary Medical Oncologist | Cleveland Clinic
Advertisement
Get the latest UC research straight to your inbox.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.